Related by context. All words. (Click for frequent words.) 66 Investigational 64 New Drug IND 60 IND Investigational New 60 INDs 59 Ing Groep NV 58 IND enabling 58 New Drug Application 58 IND submission 57 Biologics License Application BLA 57 Biologic License Application 56 Biologics License Application 56 Clinical Trial Application 54 k premarket 54 Premarket Notification 54 Biologic License Application BLA 54 NDA submission 53 Drug Submission 53 Marketing Authorization Application 53 Premarket Approval PMA 53 Premarket Approval Application 53 registrational 52 sNDA 52 Marketing Authorisation Application MAA 52 pivotal Phase III 52 Phase III clinical 52 initiate Phase 52 Marketing Authorization Application MAA 52 preclinical 52 Phase Ib 51 Glybera R 51 Phase IIb 51 ANDAs 51 Phase IIa trial 51 investigational 51 Phase IIa 51 Marqibo 51 Investigational Device Exemption IDE 51 Marketing Authorisation Application 51 Phase IIb clinical 51 Clinical Trial Authorization 51 XOMA 3AB 51 BLA submission 50 BLA filing 50 GLP toxicology studies 50 confirmatory Phase III 50 Zenvia ™ 50 Phase 2b trial 50 HCV polymerase inhibitor 50 Icatibant 50 Application BLA 50 balsalazide tablet 50 ALN PCS 50 Phase III trials 49 PREOS 49 Phase III clinical trials 49 Investigational Device Exemption 49 PDE4 inhibitor 49 Phase Ib study 49 phase IIa 49 omacetaxine mepesuccinate 49 Iluvien ® 49 ruxolitinib 49 IND CTA 49 Remoxy TM 49 registrational trial 49 Phase IIb trial 49 tiapamil 49 Soliris TM eculizumab 49 Biological License Application 49 Phase IIIb clinical 48 novel mTOR inhibitor 48 investigational compound 48 Cloretazine ® 48 Files Investigational 48 Initiate Phase 48 MEK inhibitor 48 maturation inhibitor 48 clinical trials 48 FDA Approvable Letter 48 Phase IIb trials 48 PNP inhibitor 48 Glybera 48 PMA submission 48 IND Application 48 Phase 2b clinical 48 Phase 2b clinical trials 48 Phase 1b clinical 48 MONOVISC 48 phase IIa clinical 48 histone deacetylase HDAC inhibitor 48 PNT# 48 PLK1 SNALP 48 Bronchitol 48 Alvesco R 48 oral prodrug 48 Rhucin 48 UPLYSO 48 Lenocta TM 48 injectable formulation 48 Prednisporin TM 48 Luveniq 48 KSP inhibitor 47 investigational pan BCR 47 nonclinical studies 47 EOquin 47 initiate Phase Ib 47 mitogen activated ERK kinase 47 PREOS R 47 Phase IIa clinical 47 Phase 2a clinical 47 Zelrix 47 subcutaneous formulation 47 Pivotal Phase III 47 Archexin 47 TKM ApoB 47 MAA submission 47 Market Approval PMA 47 XL# anticancer compounds 47 Phase III 47 Complete Response 47 Esbriet pirfenidone 47 BLAs 47 Fentanyl TAIFUN R 47 maribavir 47 Panzem R 47 severe hypercholesterolemia 47 prGCD 47 Phase 2b study 47 initiate Phase 2a 47 Corlux 47 vilazodone 47 NEBIDO R 47 FDA approvable letter 47 sBLA 47 oral protease inhibitor 47 CIP TRAMADOL ER 47 ANAVEX #-# [003] 47 CB2 selective receptor agonist 47 clinical 47 Linjeta TM 47 preclinical toxicology 47 clinical trial 47 Phase 2b 47 HCV protease inhibitor 47 lomitapide 47 AP# [003] 47 non nucleoside inhibitor 47 Drug Applications INDs 47 Orphan Drug Status 47 Phase Ib clinical 47 CIP ISOTRETINOIN 47 AQ4N 47 Phase 2a trial 47 Fx #A 46 Fodosine 46 RDEA# 46 phase IIb clinical 46 investigational humanized monoclonal antibody 46 Vilazodone 46 ALN TTR 46 IIa trial 46 preclinical studies 46 Lixisenatide 46 phase IIb study 46 Flutiform ™ 46 Dyloject TM 46 ANTEGREN 46 ATL# [001] 46 Biologics Licensing 46 generation purine nucleoside 46 defensin mimetic antibiotic 46 PrevOnco 46 alogliptin 46 Soliris eculizumab 46 Guanilib 46 Troxatyl 46 Phase 2a 46 submit Biologics License 46 application sNDA 46 PIX# trial 46 Zenvia TM 46 Solorel 46 teduglutide 46 Zensana 46 Hedgehog pathway inhibitor 46 Japanese Encephalitis vaccine 46 oral formulation 46 P.Manning pass short 46 dextromethorphan quinidine 46 Personalized Immunotherapy 46 Camvia 46 PSN# [002] 46 CCR5 antagonist 46 Urocidin 46 NEBIDO 46 Junovan 46 investigational drug 46 Intermezzo ® NDA 46 Onconase 46 inhaled liposomal ciprofloxacin 46 Spiegelmer ® 46 Omigard 46 polymerase inhibitor 46 TREANDA 46 JAK inhibitor 46 APF# NDA 46 Drug Applications NDAs 46 Phase 2a clinical trials 46 AAG geldanamycin analog 46 Phenoptin 46 ILUVIEN ® 46 BLOOM DM 46 Phase #b/#a trial 46 Pre IND 46 LUCASSIN 46 ALN TTR# 45 ocular formulation 45 OLpur TM H2H 45 Fast Track Status 45 Pruvel 45 Orphan Drug Designation 45 NDA resubmission 45 Aerosurf 45 tasimelteon 45 Oxytrex TM 45 TQT study 45 OMAPRO ™ 45 confirmatory Phase 3 45 TKM PLK1 45 Omapro 45 VEGF Trap 45 Phase 1b trial 45 non nucleoside 45 Zenvia Phase III 45 FlutiformTM 45 candidate REP# 45 Phase Ia 45 Factor VIIa 45 Ceflatonin 45 Phase III Clinical Trial 45 Cellegesic 45 Ciclesonide 45 ANDA filings 45 Arpida 45 JZP 45 CRMD# 45 Vion Pharmaceuticals 45 LE SN# 45 dasatinib Sprycel ® 45 Initiated Phase 45 Oglemilast 45 diarrhea predominant irritable 45 udenafil 45 Dalbavancin 45 No Huddle Shotgun 45 Clevudine 45 CEQ# 45 virus HCV protease inhibitor 45 Junovan TM 45 Pivotal Phase 45 huN# DM1 45 Surfaxin LS 45 intravenous acetaminophen 45 Phase III pivotal 45 beta 1a 45 Onalta ™ 45 initiate Phase IIa 45 Premarket Approval 45 Phase III randomized controlled 45 QRxPharma 45 Investigational Oral 45 iloperidone 45 BEMA TM Fentanyl 45 miconazole Lauriad R 45 sterile lidocaine patch 45 Hedgehog antagonist 45 IMC #B 45 PEG SN# 45 Drug Submission NDS 45 Familial Adenomatous Polyposis FAP 45 Pharmexa 45 orally administered 45 Amoxicillin PULSYS 45 Aridol 45 PROVENGE sipuleucel T 45 Telatinib 45 midstage trials 45 KRYSTEXXA TM pegloticase 45 VitiGam 45 include Phenoptin TM 45 PHASE III 45 HGS# 45 novel histone deacetylase 45 Orathecin 45 oral ridaforolimus 45 RhuDex ® 45 PS# [001] 45 Phase IIa clinical trials 45 initiate Phase 2b 45 IAP inhibitors 45 Phase #/#a trial 45 supplemental Biologics License Application 45 lorvotuzumab mertansine 45 peginesatide 45 HIV integrase inhibitor 45 antibody MT# 45 SPD# 45 Intermezzo R 45 multiple ascending dose 45 OROS R Hydromorphone 45 IND #-#,#-# 45 orphan designation 45 cystinosis patients 45 Extended Release Capsules 45 investigational hepatitis B 45 Plenaxis TM 45 initiate Phase IIb 45 highly selective adenosine 45 AGENDA 45 generation calcineurin inhibitor 45 adecatumumab MT# 45 FOLOTYN ® 45 Amigal 45 IAP inhibitor 45 Preclinical studies suggest 45 Bremelanotide 44 Kevetrin 44 investigational hepatitis C 44 targeted radiotherapeutic 44 INCB# [001] 44 Augment Injectable 44 ATL# [002] 44 MIKE PENCE R 44 lucinactant 44 IL# PE#QQR 44 Dyloject 44 lorcaserin NDA 44 RNAi therapeutic targeting 44 DermTech International 44 Phase 1a 44 JAK1 44 Phase IIa trials 44 NM# [001] 44 opioid bowel dysfunction 44 CORT # 44 pharmacokinetics PK 44 MOZOBIL 44 ATPace TM 44 registrational studies 44 StaphVAX 44 AzaSite Plus 44 Phase 1a clinical 44 Roflumilast 44 subcutaneously administered 44 Prulifloxacin 44 HDACi 44 recombinant human 44 Orphan Drug designation 44 MOR# 44 % uracil topical 44 MAA 44 MAXY VII 44 trastuzumab DM1 T DM1 44 ONCONASE R 44 preclinical efficacy 44 BMN 44 mTOR inhibitor 44 NASDAQ CXSP announced 44 GLP1 INT TM 44 Anturol ® 44 omacetaxine 44 oritavancin 44 GLPG# 44 investigational HCV polymerase 44 FDA Complete Response 44 pixantrone NDA 44 phase Ib clinical 44 vemurafenib 44 CRF1 receptor antagonist 44 Augment Bone Graft 44 Topical Interferon Alpha 2b 44 Phase 1b 44 RhuDex TM 44 J.Addai 44 Successfully Completes Phase 44 ADVEXIN 44 Shigamabs ® 44 FDA Accepts 44 TRX1 44 Anavex #-# 44 ganetespib 44 pivotal Phase 44 SYR 44 alvimopan 44 Mozobil 44 Deferiprone 44 supplemental biologics 44 Zingo TM 44 cannabinor 44 Files IND 44 Iluvien 44 crofelemer 44 Drug Applications ANDAs 44 CLIA waiver 44 dalbavancin 44 Phase IIb Trial 44 NDA BLA 44 Belinostat 44 histone deacetylase inhibitor 44 Ereska 44 AERx iDMS 44 Patient Enrolment 44 SYCREST 44 Civacir 44 OX1 44 RIGScan 44 SinuNase ™ 44 Iluvien TM 44 JAK2 inhibitor 44 ITAX 44 Onrigin 44 molecular imaging radiopharmaceutical 44 C1 inhibitor rhC1INH 44 acting muscarinic antagonist 44 Epothilone 44 candidates bavituximab 44 Loramyc 44 RAV# 44 orally administered inhibitor 44 torezolid 44 DC Bead 44 II Clinical Trial 44 Phase IIb Clinical Trial 44 Triolex 44 Cintredekin Besudotox 44 M Vax 44 MK #B 44 Phase IIb clinical trials 44 tafamidis 44 Aryplase 44 Evoltra R 44 XiDay 44 Ruconest 44 pandemic influenza vaccine 44 OvaRex R 44 anticancer compound 44 Genz # 44 Aurora Kinase 44 Liposomal 44 LymphoStat B TM 44 potently inhibit 44 zanolimumab 44 phase Ib 44 INA bt 44 ZYBRESTAT TM 44 NOXXON 44 indiplon capsules 44 ALN HPN 44 GRAS notification 43 Zalbin 43 Aurora kinase inhibitor 43 Cloretazine R 43 BRILINTA 43 SPARLON 43 Vitaros 43 cutaneous T 43 JOULFERON 43 EGS# 43 Chemical Entity NCE 43 ADVEXIN p# therapy 43 torezolid phosphate 43 MyVax R 43 VQD 43 cell lymphoma CTCL 43 apaziquone 43 fusion inhibitor 43 PF # [001] 43 Tezampanel 43 lexidronam injection 43 ghrelin antagonist 43 assessing T DM1 43 DMFs 43 novel prodrug 43 Sanvar R 43 R#/MEM # 43 Submits Investigational 43 Marketing Approval PMA 43 acyclovir Lauriad R 43 ATL/TV# 43 DPX Survivac 43 ANDA 43 phase 2a 43 miconazole Lauriad 43 Linjeta 43 TKB# 43 APEX PD 43 Bosutinib 43 Phase II 43 anti botulism antibody 43 Phase 2a Trial 43 ORE# 43 Prodarsan 43 VIAject R 43 celgosivir 43 HCV polymerase 43 HspE7 43 OMAPRO 43 seliciclib CYC# 43 INCB# [002] 43 ABL inhibitor 43 Manja Bouman CEO 43 KRN# 43 Rhucin R 43 Aroplatin 43 NPSP# 43 AEZS 43 Contrave NDA 43 Caprospinol 43 vinorelbine emulsion 43 PD LID 43 Bicifadine 43 therapeutics 43 BEMA Granisetron 43 CINTREDEKIN BESUDOTOX 43 OXIGON 43 silodosin 43 PDUFA date 43 Valtropin 43 Menerba 43 vivo toxicology 43 pharmacological chaperone 43 Aplidin 43 non nucleoside HCV 43 Orphan Status 43 TELINTRA 43 Alzhemed TM 43 autologous cellular immunotherapy 43 orphan drug 43 Australian Therapeutic Goods 43 hypoxia activated prodrug 43 Simulect 43 glucokinase activator 43 therapeutic antibody 43 Solasia 43 NOX E# 43 sNDA submission 43 Phase Ib II 43 Cimzia TM 43 LEP ETU 43 E1 INT TM 43 Orthopedic Advisory Panel 43 immunotherapeutic vaccine 43 palifosfamide 43 Somatuline R Autogel R 43 RIGScan ™ 43 clofarabine 43 zileuton CR 43 perifosine KRX 43 P#X# antagonist 43 Troxatyl TM 43 QLT# 43 rALLy 43 PHARMACEUTICALS INC 43 Entereg TM 43 NKTR 43 LidoPAIN SP 43 oral proteasome inhibitor 43 XmAb ® 43 phase IIb 43 elotuzumab 43 * BIO Pte 43 investigational oral hepatitis C 43 Tamibarotene 43 alvespimycin 43 highly selective inhibitor 43 Pfizer maraviroc 43 BAL# [002] 43 Shigamabs R 43 ATryn ® 43 MBP# [001] 43 MVA HPV IL2 43 sumatriptan DosePro 43 ChemGenex Pharmaceuticals Limited 43 Voraxaze 43 Trofex 43 pharmacokinetic PK 43 ACUROX 43 Octreotide 43 bardoxolone 43 Clinical Trial 43 HoFH 43 Cloretazine R VNP#M 43 LibiGel ® 43 ARIKACE ™ 43 GALNS 43 PREGNANT Study 43 RH1 43 investigational oral 43 fidaxomicin 43 epothilone 43 Valortim TM 43 Biopartners 43 Oracea TM 43 RNAi therapeutic 43 diabetic neuropathic pain 43 voclosporin 43 Safinamide 43 ATHX 43 Trimesta 43 Virulizin 43 next generation URAT1 43 MT# MEDI 43 Vicriviroc 43 MORAb 43 BLA 43 PrevOnco ™ 43 ZEGERID Chewable Tablets 43 Approvable Letter 43 Integrase Inhibitor 43 VIAject 43 Hematide ™ peginesatide 43 UCB Cimzia 43 investigational antiplatelet agent 43 Factor VIIa inhibitor 43 rhC1INH 43 dose escalation clinical 43 anti CD3 monoclonal 43 Phase Ib clinical trials 43 Zybrestat 43 intravenous formulation 43 Nasdaq TSPT 43 Phase IIIb 43 Meets Primary Endpoint 43 Therapeutic Vaccine 43 LUMINATE 43 Teysuno 43 Oncoscience AG 43 ICA # 43 Drug Application 43 Memryte 43 Annamycin 43 Ceflatonin R 43 Flutiform 43 SUVN 43 DAVANAT ® 43 APF# 43 CDK inhibitor 43 ONCONASE 43 Biologics License Applications 43 SUCCEED trial 43 Preos 43 NexACT 43 Firdapse 43 histamine dihydrochloride 43 ARRY # 43 Surfaxin 43 PROGENSA R 43 novel orally administered 43 Phase lll 43 AcelRx 43 PANVAC VF 43 GATTEX 43 Ozarelix 43 FavId 43 mGluR5 negative 43 Solzira 43 compound PMX # 43 generation NNRTI 43 Nexavar ® 43 dirucotide 43 Drug Candidate 43 GSK# [002] 43 Master File DMF 43 outlicensed 43 Risperidone Oral Solution 43 HDAC Inhibitor 43 Omacetaxine 43 Ketotransdel 43 Initiate Clinical Trial 43 Phase #b/#a 43 GlycoPEG GCSF 42 PEP# [003] 42 SAR# [002] 42 Excellagen 42 HSP# inhibitor 42 generation PNP inhibitor 42 BiTE antibody 42 PEG PAL 42 Zenpep 42 Orphan Drug designations 42 DDP# 42 NASDAQ ISPH announced 42 Suven 42 VEGF inhibitor 42 recombinant biopharmaceutical 42 long acting muscarinic 42 NVA# 42 Inc. Amex SYI 42 liprotamase 42 inhaled formulation 42 Sudhir Agrawal D.Phil 42 Phase #/#a 42 Pharmacokinetics PK 42 exon skipping 42 Exocrine Pancreatic Insufficiency 42 NDA Submission 42 randomized controlled Phase 42 BENLYSTA 42 Phase IIa proof 42 Hepatitis C HCV 42 Arzerra ofatumumab 42 tezampanel NGX# 42 RNAi Therapeutic 42 ACHN 42 miconazole Lauriad ® 42 Actemra tocilizumab 42 safflower produced 42 elvucitabine 42 antibody MAb 42 voreloxin 42 PF # [002] 42 Onco TCS 42 multicenter Phase 42 humanized monoclonal antibody 42 Rhucin ® 42 ANDA abbreviated 42 SFDA approval 42 humanized monoclonal 42 ALKS 42 TMC# [002] 42 ULTRASE 42 Firazyr 42 initiated Phase Ib 42 Anidulafungin 42 topical anti infective 42 ZFP Therapeutics 42 OncoVEX 42 Sanctura XR 42 T Pred 42 topical formulation 42 TRANSDUR Sufentanil 42 amifampridine phosphate 42 Cardiac Cryoablation System 42 EVIZON ™ 42 Daclizumab 42 Talotrexin 42 PRLX # 42 Initiates Phase II 42 SCIB1 42 Oral lyn 42 vidofludimus 42 Joulferon 42 dose escalation Phase 42 SPRYCEL ® 42 zolpidem tartrate sublingual tablet 42 Curaxin 42 TRANSFORMS 42 Prodarsan ® 42 BEMA Fentanyl 42 severe gastroparesis 42 Preclinical studies 42 APTIMA HPV assay 42 TBC# 42 oral anticancer 42 ponatinib 42 BRIM3 42 rhLF 42 AMPAKINE CX# 42 novel defensin mimetic 42 oral taxane 42 cytotoxic conjugate 42 rolling Biologics License 42 carfilzomib 42 small molecule tyrosine 42 PG# [004] 42 Phase #b/#a clinical 42 Cannabinor 42 hoFH 42 granted Ortec 42 HepeX B 42 OLpur TM MD 42 oral methylnaltrexone 42 LHRH antagonist 42 Phase IIa Clinical Trial 42 Cinryze ™ 42 Fodosine TM 42 metastatic hormone refractory 42 ALGRX 42 Behcet uveitis 42 ISENTRESS raltegravir 42 EndoTAG TM -1 42 FDA Investigational Device 42 fipamezole 42 file INDs 42 CUSF application 42 Shigamabs 42 OncoVEX GM CSF 42 oral nucleoside analogue 42 REMOXY R 42 Polymer Microspheres 42 Nimotuzumab 42 Phase 2b Clinical Trial 42 Dose Ranging Study 42 oxybutynin ATD TM 42 Loramyc R 42 RELOVAIR ™ 42 vinflunine 42 IDX# 42 Panzem 42 SNS# T 42 INT# [002] 42 Cutanea 42 BLP# Liposome Vaccine 42 deforolimus 42 Davanat 42 myelodysplastic myeloproliferative diseases 42 intranasal formulation 42 FIRMAGON R 42 Vertex hepatitis C 42 Phase IIA 42 Perflubutane Polymer Microspheres 42 Pafuramidine 42 IMA# 42 Li Fraumeni Syndrome 42 Tramadol ER 42 XL# XL# XL# 42 pharmacokinetic studies 42 Afresa 42 PDX pralatrexate 42 ALTROPANE R 42 Onsolis 42 Frova ® 42 luliconazole 42 Drug Eluting Stent System 42 Panzem ® 42 EPCT 42 CryoSeal 42 PMA Supplement 42 prucalopride 42 Orazol 42 k Premarket Notification 42 apricitabine ATC 42 Phase 2b Study 42 Velcade bortezomib 42 Stedesa 42 CUDC 42 tramiprosate Alzhemed TM 42 ALD# 42 OTCQX QRXPY 42 YM BioSciences 42 SILENOR TM 42 SURFAXIN 42 inhibitor VX 42 investigational atypical antipsychotic 42 Velac 42 product candidate Lpathomab 42 Amrubicin 42 tezampanel 42 Vicinium TM 42 DB# [003] 42 outlicensing 42 Completes Patient Enrollment 42 Novelos 42 Plicera 42 Tranzyme Pharma 42 Restanza 42 gemcitabine Gemzar ® 42 CD# CEA 42 triciribine phosphate monohydrate 42 Azedra 42 CRTX 42 Phase IIb III 42 budesonide MMX 42 Oracea 42 indiplon 42 Orphan Drug status 42 Balaglitazone 42 Bioral R 42 Augment TM 42 Convivia TM 42 Exelbine NDA 42 FDA APPROVES 42 JZP 6 42 antisense inhibitor 42 PSN# [001] 42 antisense drug 42 triphendiol 42 POSIDUR TM ELADUR TM 42 Phase 2b Trial 42 StemEx R 42 sumatriptan injection 42 sulodexide 42 IMGN# 42 aurora kinase 42 Surfaxin lucinactant 42 Antegren 42 Xyfid TM 42 AMD# [002] 42 DPP4 inhibitor 42 Paragraph IV certifications 42 amrubicin 42 clevudine 42 DAVANAT R 42 IIa clinical 42 EOquin TM 42 Novolimus 42 THR beta agonist 42 resubmission 42 Angiocept 42 LEVADEX ™ 42 ATryn R 42 AEG# 42 Huntexil 42 forodesine hydrochloride 42 HEPLISAV TM 42 Janus Kinase 42 REMOXY 42 NADiA ProsVue 42 selective androgen receptor modulator 42 linaclotide 42 Jingxin Pharma 42 Lymphoseek ® 42 Nasdaq ENZN 42 ZP# [002] 42 liposomal formulation 42 integrase inhibitor 42 EGRIFTA TM 42 PRTX 42 initiate Phase 1b 42 methylnaltrexone 42 mertansine 42 novel orally bioavailable 42 Telavancin 42 faropenem 42 Silodosin 42 QRX 42 EVIZON TM 42 vascular disrupting agent 42 FTY# fingolimod 42 PRECISE trial 42 Acetavance TM 42 Ambrisentan 42 IIa trials 42 LB# [003] 42 Laquinimod 42 orally dosed 42 Vascular Disrupting Agent 42 Verigene System 42 Gendux 42 Posiphen 42 Approvable letter 42 CORT # estimates 42 TOCOSOL Paclitaxel 42 oral antiviral 42 Tranzyme 42 sNDAs 42 4SC 42 Serdaxin 42 Ganciclovir 42 CCR9 antagonist 42 Phase IIB 42 MT#/MEDI-# 42 INC# 42 Sosei 42 AeroLEF 42 StaphVAX R 42 Anturol TM 42 NASDAQ INGN 42 hematological cancers 42 OTCBB PYTO 42 Ampligen r 42 TLR8 agonist 42 MK #A [001] 42 topically applied SEPA 42 biogeneric 42 pharmacodynamic PD 42 Circ Pharma 41 Santhera 41 IIb clinical trial 41 Nabi HB Intravenous 41 Tesmilifene 41 DMEP 41 Receives Orphan Drug Designation 41 Augment ™ 41 trodusquemine MSI 41 Receptor Agonist 41 Difimicin 41 Neurodex TM 41 nimotuzumab 41 Enobia 41 E CENP E 41 refractory APL 41 LAF# 41 Maribavir 41 Ecallantide 41 Fast Track designations 41 Cimzia ® 41 pan histone deacetylase 41 Indiplon